Abstract:Although many researchers of Parkinson's disease (PD) have shifted their focus from the central nervous system (CNS) to the peripheral blood, a significant knowledge gap remains between PD severity and the peripheral immune response. In the current study, we aimed to map the peripheral immunity atlas in peripheral blood mononuclear cells (PBMCs) from PD patients and healthy controls using single-cell RNA sequencing (scRNA-seq). Our study employed scRNA-seq analysis to map the peripheral immunity atlas in PD by profiling PBMCs from PD-Early, PD-Late patients and matched controls. By enlarging the blood sample size, we validated the roles of NK cells in numerous immune-related biological processes. We also detected the infiltration of NK cells into the cerebral motor cortex as the disease progressed, using human brain sections, and elucidated the communication between the periphery and CNS and its implications for PD. As a result, cell subpopulation atlases in PBMCs from PD patients and healthy controls along with differentially expressed genes in NK cells were identified by scRNA-seq analysis, representing 6 major immune cell subsets among which NK cells declined in the progression of PD. We further validated NK cell reduction in increasing samples and found that they participated in numerous immune-related biological processes and infiltration into the cerebral motor cortex as the disease proceeded, evidencingd the close communication between the peripheral immune response and CNS. Strikingly, XCL2 positively correlated with PD severity, with good predictive performance of PD and specific expression in subclusters C2 and C5 of NK cells. All these findings delineated the critical role of peripheral immune response mediated by NK cells in the pathogenesis of PD. NK cell-specific XCL2 could be used as a diagnostic marker for treating PD. The indispensable function of NK cells and NK cell-specific molecular biomarkers highlighted the implication of the peripheral immune response in PD progression. Trial registration: ChiCTR, ChiCTR1900023975. Registered 20 June 2019 - Retrospectively registered, https://www.chictr.org.cn/showproj.html?proj=31035 .

New Insights into Immune-Mediated Mechanisms in Parkinson's Disease

The immune system in Parkinson's disease: what we know so far

Inflammation and immune dysfunction in Parkinson disease

Neuroinflammation in Parkinson's Disease - Putative Pathomechanisms and Targets for Disease-Modification

Immune-related biomarkers for Parkinson's disease

The Role of Immune Dysfunction in Parkinson's Disease Development

Regulation of Immune-Driven Pathogenesis in Parkinson’s Disease by Gut Microbiota

Periphery and brain, innate and adaptive immunity in Parkinson's disease

Immunotherapy in Parkinson’s disease: Current status and future directions

The systemic immune response in Parkinson's disease: focus on the peripheral immune component

Single-cell RNA sequencing reveals peripheral immunological features in Parkinson's Disease

NEUROINFLAMMATION AND IMMUNE DYSFUNCTION IN THE PATHOGENESIS OF PARKINSON’S DISEASE

Inflammatory Mechanisms in Parkinson’s Disease: From Pathogenesis to Targeted Therapies

Dendritic cells in Parkinson's disease: regulatory role and therapeutic potential

Cytokine and Chemokine Map of Peripheral Specific Immune Cell Subsets in Parkinson's Disease

Experimental Models to Study Immune Dysfunction in the Pathogenesis of Parkinson's Disease

Neuroinflammatory Responses and Parkinson' Disease: Pathogenic Mechanisms and Therapeutic Targets

Therapeutic Strategies for Immune Transformation in Parkinson's Disease

The Challenge of the Pathogenesis of Parkinson's Disease: Is Autoimmunity the Culprit?

Parkinson’s disease: etiopathogenesis and treatment

Disease mechanisms as subtypes: Inflammation in Parkinson disease and related disorders